KZIA vs. CARM, AADI, LVTX, LTRN, SYRS, KZR, PASG, BGXX, ELEV, and TARA
Should you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Carisma Therapeutics (CARM), Aadi Bioscience (AADI), LAVA Therapeutics (LVTX), Lantern Pharma (LTRN), Syros Pharmaceuticals (SYRS), Kezar Life Sciences (KZR), Passage Bio (PASG), Bright Green (BGXX), Elevation Oncology (ELEV), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry.
Carisma Therapeutics (NASDAQ:CARM) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings, media sentiment and community ranking.
Carisma Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 2.13, suggesting that its share price is 113% more volatile than the S&P 500.
Carisma Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 700.00%. Kazia Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 438.36%. Given Carisma Therapeutics' higher probable upside, equities analysts clearly believe Carisma Therapeutics is more favorable than Kazia Therapeutics.
Kazia Therapeutics received 66 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 52.67% of users gave Kazia Therapeutics an outperform vote.
Kazia Therapeutics has lower revenue, but higher earnings than Carisma Therapeutics.
In the previous week, Carisma Therapeutics had 1 more articles in the media than Kazia Therapeutics. MarketBeat recorded 1 mentions for Carisma Therapeutics and 0 mentions for Kazia Therapeutics. Carisma Therapeutics' average media sentiment score of 0.55 beat Kazia Therapeutics' score of 0.00 indicating that Carisma Therapeutics is being referred to more favorably in the media.
Kazia Therapeutics has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -350.08%. Kazia Therapeutics' return on equity of 0.00% beat Carisma Therapeutics' return on equity.
44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are held by institutional investors. 17.0% of Carisma Therapeutics shares are held by insiders. Comparatively, 1.0% of Kazia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Carisma Therapeutics beats Kazia Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Kazia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kazia Therapeutics Competitors List
Related Companies and Tools
